当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
FluBlok, Influenza Vaccine
申请企业
Protein Sciences Corporation
药品名称
FluBlok, Influenza Vaccine
承诺描述
Deferred pediatric safety, immunogenicity and efficacy study under PREA for the prevention of disease caused by influenza virus subtypes A and types B contained in Flublok Quadrivalent in pediatric patients ages 3 years through 17 years.
承诺状态描述
The study has not been initiated, but does not meet the criterion for delayed.